journal article·2018-11-12Open access

Core/shell multicellular spheroids on chitosan as in vitro 3D coculture tumor models

Ching-Wen Tsai, Jyh-Horng Wang, Tai-Horng Young

Abstract

An ideal in vitro drug screening model is important for the drug development. In addition to monoculture systems, 3 dimensional (3D) coculture systems are extensively used to simulate the in vivo tumor microenvironment as cell-cell and cell-extracellular matrix interactions within the tumor tissues can be mimicked. In this study, in vitro 3D suspension coculture multicellular spheroids with core/shell cell distribution were developed on chitosan-coated surfaces. Based on the characteristic of chitosan inhibiting cell adhesion, SW620 (colon cancer cell line), 3A6 (mesenchymal stem-like cell line) and Hs68 (foreskin fibroblast line) cells could aggregate to form 3D coculture spheroids with intimate cell contacts. When cells were cocultured on chitosan, 3A6 and Hs68 cells always located in the core of spheroids and were completely enveloped by SW620 cells due to their N-cadherin protein expression following the differential adhesion hypothesis. The core cells could be the feeder layers to stimulate the shell SW620 cells to enhance their mitochondria activity. Moreover, 3D coculture core/shell multicellular spheroids could enhance the resistance of SW620 cells against the cytotoxicity effect of chemotherapy drugs. To sum up, based on the specificity of the core/shell coculture multicellular spheroids, a novel in vitro tumor model was proposed in this study.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: 3D Printing in Biomedical Research · Cancer Cells and Metastasis · Cellular Mechanics and Interactions

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Institute of Biomedical Engineering, National Taiwan University

Department of Orthopedic Surgery, National Taiwan University Hospital

References (56)

Show source-provided references
1. 10.1016/j.jbiotec.2010.01.01210.1016/j.jbiotec.2010.01.012 ↗
2. 10.1016/j.biomaterials.2015.09.01710.1016/j.biomaterials.2015.09.017 ↗
3. 10.1016/j.biomaterials.2014.09.01010.1016/j.biomaterials.2014.09.010 ↗
4. 10.1016/j.jconrel.2012.04.04510.1016/j.jconrel.2012.04.045 ↗
5. 10.1021/acs.molpharmaceut.5b0042610.1021/acs.molpharmaceut.5b00426 ↗
6. 10.1016/j.ydbio.2004.11.01210.1016/j.ydbio.2004.11.012 ↗
7. 10.1021/acs.biomac.5b0103210.1021/acs.biomac.5b01032 ↗
8. 10.1039/c5ib00157a10.1039/c5ib00157a ↗
9. 10.3109/0265204970900682010.3109/02652049709006820 ↗
10. 10.2174/138920103348974810.2174/1389201033489748 ↗
11. 10.1016/j.jss.2005.12.01310.1016/j.jss.2005.12.013 ↗
12. 10.1016/j.carbpol.2013.03.03410.1016/j.carbpol.2013.03.034 ↗
13. 10.1002/mabi.20070018810.1002/mabi.200700188 ↗
14. 10.3390/md1304215810.3390/md13042158 ↗
15. 10.1371/journal.pone.014074710.1371/journal.pone.0140747 ↗
16. 10.1080/21691401.2017.139487310.1080/21691401.2017.1394873 ↗
17. 10.7150/jca.2.50710.7150/jca.2.507 ↗
18. 10.1038/srep0233210.1038/srep02332 ↗
19. 10.1515/pac-2016-040510.1515/pac-2016-0405 ↗
20. 10.1016/j.taap.2012.07.01310.1016/j.taap.2012.07.013 ↗
21. 10.1016/j.biomaterials.2011.11.04910.1016/j.biomaterials.2011.11.049 ↗
22. 10.1089/ten.tea.2008.025110.1089/ten.tea.2008.0251 ↗
23. 10.18632/oncotarget.490210.18632/oncotarget.4902 ↗
24. Ji X, Ji J, Shan F, et al. Cancer-associated fibroblasts from NSCLC promote the radioresistance in lung cancer cell lines. International Journal of Clinical and Experimental Medicine. 2015;8:7002–7008.
25. 10.1186/scrt22110.1186/scrt221 ↗
26. 10.3892/ijmm.2016.255610.3892/ijmm.2016.2556 ↗
27. 10.3390/cancers704090210.3390/cancers7040902 ↗
28. Li XY, Hu SQ, Xiao L. The cancer-associated fibroblasts and drug resistance. Eur Rev Med Pharmacol Sci. 2015;19:2112–2119.
29. 10.1016/j.taap.2011.07.01310.1016/j.taap.2011.07.013 ↗
30. 10.1016/j.biomaterials.2012.08.05210.1016/j.biomaterials.2012.08.052 ↗
31. 10.1021/bm301928u10.1021/bm301928u ↗
32. 10.1016/j.jbiosc.2013.06.01510.1016/j.jbiosc.2013.06.015 ↗
33. 10.1002/ijch.20120001310.1002/ijch.201200013 ↗
34. 10.1098/rsif.2014.006510.1098/rsif.2014.0065 ↗
35. 10.1371/journal.pone.012794810.1371/journal.pone.0127948 ↗
36. 10.1111/joa.1225710.1111/joa.12257 ↗
37. 10.1038/srep0646810.1038/srep06468 ↗
38. 10.1016/j.biomaterials.2009.02.04710.1016/j.biomaterials.2009.02.047 ↗
39. 10.1002/bit.2439910.1002/bit.24399 ↗
40. 10.1016/j.jbiotec.2015.01.00210.1016/j.jbiotec.2015.01.002 ↗
41. 10.1007/s10529-016-2218-910.1007/s10529-016-2218-9 ↗
42. 10.1186/1423-0127-17-6410.1186/1423-0127-17-64 ↗
43. 10.1242/dev.102.4.63910.1242/dev.102.4.639 ↗
44. 10.1152/physrev.00004.201010.1152/physrev.00004.2010 ↗
45. 10.1016/0092-8674(94)90209-710.1016/0092-8674(94)90209-7 ↗
46. 10.18632/oncotarget.609810.18632/oncotarget.6098 ↗
47. 10.1177/002203451142339310.1177/0022034511423393 ↗
48. 10.1387/ijdb.041810rf10.1387/ijdb.041810rf ↗
49. 10.1016/S0012-1606(02)00016-710.1016/S0012-1606(02)00016-7 ↗
50. 10.1073/pnas.97.17.946710.1073/pnas.97.17.9467 ↗
51. 10.1016/j.actbio.2013.09.00310.1016/j.actbio.2013.09.003 ↗
52. 10.1387/ijdb.041793ld10.1387/ijdb.041793ld ↗
53. 10.1101/cshperspect.a00294910.1101/cshperspect.a002949 ↗
54. 10.1101/gad.148680610.1101/gad.1486806 ↗
55. 10.1073/pnas.090534910610.1073/pnas.0905349106 ↗
56. 10.1016/j.bbcan.2008.07.00210.1016/j.bbcan.2008.07.002 ↗